依折麦布对高脂血症合并肝损伤患者的治疗效果

Efficacy of ezetimibe on patients with hyperlipidemia accompanying with liver damage

目的观察依折麦布对高脂血症合并肝损伤患者的疗效。方法单纯高胆固醇血症合并肝损伤(A组,30例)和混合型高脂血症合并肝损伤(B组,35例)患者服用依折麦布10mg/d;用酶法测定治疗前及治疗4、8周时的血清AST、ALT、肌酸激酶(CK)、血LDL-C、TC和TG水平。结果与治疗前比较,依折麦布治疗8周时,B组AST、ALT、CK明显下降(P<0.05),两组LDL-C、TC、TG水平均明显下降,B组下降更明显(P<0.05)。结论依折麦布单药治疗高脂血症合并肝损伤患者安全、有效。

Objective To observe the efficacy of ezetimibe on the patients with hyperlipidemia accompanying with liver damage.Methods The patients with hypercholesterolemia（group A,30 cases） or with mixed hyperlipidemia（group B,35 cases）,who were accompanied by liver damage,were treated with ezetimibe 10 mg/d.Serum levels of aspartate aminotransferase（AST）,alanine aminotransferase（ALT）,creatine kinase（CK） low density lipoprotein cholesterol（LDL-C）,total cholesterol（TC） and triglyceride（TG） were assessed by ELISA before,on the 4th and 8th week during treatment.ResultsCompared to before,serum levels of AST,ALT and CK on the 8th week of treatment were significantly reduced in group B（P0.05）,and those of LDL-C,TC and TG were decreased in both groups,which was even more in group B（P0.05）.Conclusion Treatment with ezetimibe alone is effective and safe in the patients with hyperlipidemia accompanying with liver damage.